

Intrapartum care for healthy women and babies

[B] Initial assessment of women reporting prelabour rupture of membranes

NICE guideline number CG190 (update)

Evidence review underpinning recommendations 1.7.1, 1.7.2, 1.7.6, 1.7.7 and 1.7.11 in the NICE guideline

April 2023

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2023. All rights reserved. Subject to [Notice of rights](#).

ISBN:

Contents

Initial assessment after prelabour rupture of membranes.....	6
Review question.....	6
Introduction.....	6
Summary of the protocol.....	6
Methods and process.....	7
Effectiveness.....	7
Summary of included studies.....	7
Summary of the evidence.....	7
Economic evidence.....	8
Economic model.....	8
The committee’s discussion and interpretation of the evidence.....	8
Recommendations supported by this evidence review.....	9
References – included studies.....	9
Appendices.....	10
Appendix A Review protocols.....	10
Review protocol for review question: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?.....	10
Appendix B Literature search strategies.....	17
Literature search strategies for review question: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?.....	17
Review question search strategies.....	17
Health economics search strategies.....	20
Appendix C Effectiveness evidence study selection.....	25
Study selection for: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?.....	25
Appendix D Evidence tables.....	26
Evidence tables for review question: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?.....	26
Appendix E Forest plots.....	27
Forest plots for review question: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?.....	27
Appendix F GRADE tables.....	28
GRADE tables for review question: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?.....	28
Appendix G Economic evidence study selection.....	29
Study selection for: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?.....	29
Appendix H Economic evidence tables.....	30
Economic evidence tables for review question: What is the optimum timeframe	

	between a mother reporting possible PRoM and face-to-face clinical review?	30
Appendix I	Economic model	31
	Economic model for review question: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?.....	31
Appendix J	Excluded studies	32
	Excluded studies for review question: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?.....	32
Appendix K	Research recommendations – full details	33
	Research recommendations for review question: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?	33

1 Initial assessment after prelabour rupture 2 of membranes

3 Review question

4 What is the optimum timeframe between a mother reporting possible prelabour rupture of the
5 membranes and face-to-face clinical review?

6 Introduction

7 Pre-labour rupture of membranes (PRoM) occurs in 8% of pregnancies and around 60% of
8 these women will begin labour spontaneously within 24 hours. There are serious, but
9 uncommon risks associated with PRoM, such as cord prolapse, cord compression, placental
10 abruption and neonatal infection. It is therefore important that women with suspected PRoM
11 are assessed by a maternity care professional, but there is variation in practice and no
12 current guidance about the nature or timing of this review.

13 The aim of this review is to determine how soon after the membranes have ruptured an in-
14 person clinical review of the woman should be carried out.

15 Summary of the protocol

16 See Table 1 for a summary of the Population, Intervention, Comparison and Outcome
17 (PICO) characteristics of this review.

18 Table 1: Summary of the protocol (PICO table)

19

Population	<ul style="list-style-type: none">• Women who are pregnant with a single baby, who go into labour at preterm (< 37+ 0) or term (37 to 42 weeks of pregnancy)• Women who have had a previous caesarean birth or are having a planned caesarean birth• Women whose baby has not been identified before labour to be at high risk of adverse outcomes• Singleton babies born at term (37 to 42 weeks of pregnancy) with no previously identified problems (for example congenital malformations, genetic anomalies, intrauterine growth restriction, placental problems)
Intervention	Face-to-face clinical review advised as soon as possible (< 3 hours) after a mother telephoning to report PRoM
Comparison	Face-to-face clinical review delayed between the timeframes stated below after a mother telephoning to report PRoM <ul style="list-style-type: none">• 3 to < 6 hours• 6 to < 12 hours• 12 < 18 hours• 18 to 24 hours• > 24 hours

Outcome	Critical <ul style="list-style-type: none">• Maternal admission to ITU or high-dependency area• Mode of birth (spontaneous vaginal, instrumental vaginal, caesarean birth)• Requirement for antibiotics Important <ul style="list-style-type: none">• Induction of labour• Evidence of maternal infection including maternal pyrexia, other signs of chorioamnionitis and sepsis• Women's experience of labour and birth• Neonatal admission (includes NICU and SCBU)
----------------	--

1 *ITU: intensive therapy unit; NICU: neonatal intensive care unit; P_{Ro}M: pre-labour rupture of membranes; SCBU:*
2 *special care baby unit*

3 For further details see the review protocol in appendix A.

4 **Methods and process**

5 This evidence review was developed using the methods and process described in
6 [Developing NICE guidelines: the manual](#). Methods specific to this review question are
7 described in the review protocol in appendix A and the methods document (supplementary
8 document 1).

9 Declarations of interest were recorded according to [NICE's conflicts of interest policy](#).

10 The committee agreed that only studies conducted in high-income countries (as defined by
11 the Organisation for Economic Co-operation and Development [OECD]) should be
12 considered for inclusion because clinical monitoring following suspected rupture of
13 membranes is likely to vary between high and low/middle income countries.

14 The protocol makes reference to 'face-to-face clinical review', whereas the recommendations
15 and discussion of the evidence use the terminology 'in-person (clinical review)'. The
16 committee preferred the latter wording as the former could be taken to mean a video call.

17 **Effectiveness**

18 **Included studies**

19 A systematic review of the literature was conducted but no studies were identified which
20 were applicable to this review question.

21 See the literature search strategy in appendix B and study selection flow chart in appendix C.

22 **Excluded studies**

23 Studies not included in this review are listed, and reasons for their exclusion are provided in
24 appendix J.

25 **Summary of included studies**

26 No studies were identified which were applicable to this review question (and so there are no
27 evidence tables in Appendix D). No meta-analysis was conducted for this review (and so
28 there are no forest plots in Appendix E).

29 **Summary of the evidence**

30 No studies were identified which were applicable to this review question (and so there are no
31 GRADE tables in Appendix F).

1 **Economic evidence**

2 **Included studies**

3 A systematic review of the economic literature was conducted but no economic studies were
4 identified which were applicable to this review question.

5 **Economic model**

6 No economic modelling was undertaken for this review because the committee agreed that
7 other topics were higher priorities for economic evaluation.

8 **The committee's discussion and interpretation of the evidence**

9 **The outcomes that matter most**

10 The committee chose maternal admission to intensive therapy unit (ITU) or high-dependency
11 area, mode of birth and requirement for antibiotics as the critical outcomes for this review. As
12 both maternal admission and requirement for antibiotics are common negative outcomes for
13 women associated with PРоM, the committee agreed that these were the best indicators to
14 understand the differential effectiveness of different timeframes between a woman reporting
15 possible PРоM and an in-person clinical review. The committee also wanted to find out
16 whether different timeframes would impact the mode of birth and agreed that this was a
17 meaningful outcome for making recommendations, both in terms of the woman and the
18 health system.

19 The committee also agreed on the important outcomes for this review. As induction of labour
20 is recommended 24 hours after PРоM due to an increased risk of infection, the committee
21 wanted to include induction of labour and evidence of maternal infection as important
22 outcomes as these are likely to be impacted by different timeframes between a woman
23 reporting PРоM and an in-person face-to-face clinical review. They also agreed that it was
24 also important to find out about women's experience of labour and birth. The committee
25 recognised the great importance of women's experience of labour and birth in the presence
26 of suspected PРоM, but they were aware that data on this outcome was likely to be sparse
27 and unlikely to inform decision-making in a meaningful way, so they prioritised other
28 outcomes as critical.

29 Finally, the committee chose neonatal admission as an important outcome as this would
30 indicate whether there are any risks for the baby associated with different timeframes
31 between a woman reporting PРоM and a face-to-face clinical review.

32 **The quality of the evidence**

33 No evidence was identified which was applicable to this review question.

34 **Benefits and harms**

35 The committee noted that the protocol had included women with preterm PРоM (less than 37
36 weeks) but that the NICE guidelines on Preterm labour and birth already included
37 recommendations on the management of preterm PРоM and so they restricted their
38 discussions and recommendations to women with PРоM at term (37 to 42 weeks) which is
39 aligned with the scope of the Intrapartum care guidance.

40 No evidence was identified for the timeframe between a woman reporting possible PРоM
41 and an in-person clinical assessment, so the committee based the recommendations on their
42 experience and expertise. The committee agreed that while the recommendations would

1 reflect current practice in many Trusts, the recommendations would help to reduce variation
2 in practice and reliance on women's knowledge and perception of risk.

3 The committee discussed the triage of women reporting possible PRoM and agreed that in
4 practice, the urgency of an in-person clinical assessment should be based on the presence
5 of risk factors. The committee agreed that a list of risk factors would be useful in determining
6 the urgency of an in-person clinical assessment and decided that a woman should be seen
7 immediately if any one of these factors is present. The committee noted that some of these
8 factors would require women to be offered immediate induction, for example, if she has a
9 positive group B streptococcus test, and that recommendations relating to the timing of
10 induction were already present in the NICE guideline on Inducing labour and the NICE
11 guideline on Neonatal infection. The committee therefore included these recommendations in
12 the guideline and cross-referenced to these other relevant NICE guidelines.

13 The committee agreed that women who do not have any risk factors should be seen within 6
14 hours or as soon as possible if the woman has any concerns or wishes to be induced
15 immediately. The committee discussed the timeframe and agreed that there was no clinical
16 reason there should be a delay in an in-person clinical assessment, but they agreed that for
17 this lower risk group, the benefits of urgency should be balanced with the preferences of the
18 woman, for example wanting to spend the night at home or taking time to arrange childcare
19 and agreed that 6 hours would be a reasonable pragmatic time to allow this. The committee
20 agreed that the in-person assessment of a woman without risk factors could be carried out at
21 the woman's intended place of birth, be that at home, in a midwifery-led unit or an obstetric
22 unit. The committee noted that the deployment of community midwives may be needed in
23 cases where the woman was unable to reach the maternity unit within 6 hours, however, they
24 decided not to make a recommendation on this as this would be determined at the local
25 level.

26 The committee discussed whether to make a research recommendation as no evidence had
27 been identified but agreed that as a risk assessment was necessary for women presenting
28 with PRoM (as they had advised in their recommendations), and as this was an area where
29 maternal preference and planned place of birth also had a large impact on the decision, a
30 study randomising women to different times for assessment would be unlikely to be
31 conducted.

32 **Cost effectiveness and resource use**

33 The committee agreed that the recommendation for women with risk factors is in line with
34 current practice. However, the recommendation for women without risk factors may result in
35 more women being seen in-person within a shorter timeframe than current practice, as some
36 units currently advise longer delays than this. The committee agreed that this is unlikely to
37 have a significant impact on resources as it is only bringing the time of review for some
38 women earlier by a few hours. However, although no clinical evidence was identified, the
39 committee made a qualitative assessment that the recommendations based on their
40 expertise and experience would represent a cost-effective use of NHS resources.

41 **Recommendations supported by this evidence review**

42 This evidence review supports recommendations 1.7.1, 1.7.2, 1.7.6, 1.7.7 and 1.7.11.

43 **References – included studies**

44 **Effectiveness**

45 No evidence was identified which was applicable to this review question.

46

1 Appendices

2 Appendix A Review protocols

3 Review protocol for review question: What is the optimum timeframe between a mother reporting possible PRoM and 4 face-to-face clinical review?

5 **Table 2: Review protocol**

Field	Content
PROSPERO registration number	CRD42021266237
Review title	Initial assessment of women reporting pre-labour rupture of membranes (PRoM)
Review question	What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?
Objective	To make recommendations for the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review
Searches	<p>The following databases will be searched:</p> <ul style="list-style-type: none">• Cochrane Central Register of Controlled Trials (CENTRAL)• Cochrane Database of Systematic Reviews (CDSR)• Embase• MEDLINE & MEDLINE In-Process• International Health Technology Assessment (IHTA) database <p>Searches will be restricted by:</p> <ul style="list-style-type: none">• No date limitations• English language studies• Human studies <p>Other searches:</p>

Field	Content
	<ul style="list-style-type: none"> • Inclusion lists of systematic reviews <p>The full search strategies for the MEDLINE database will be published in the final review. For each search, the principal database search strategy is quality assured by a second information scientist using an adaptation of the PRESS 2015 Guideline Evidence-Based Checklist.</p>
Condition or domain being studied	Labour and birth
Population	<ul style="list-style-type: none"> • Women who are pregnant with a single baby, who go into labour at preterm (< 37+ 0) or term (37 to 42 weeks of pregnancy) • Women who have had a previous caesarean birth or are having a planned caesarean birth • Women whose baby has not been identified before labour to be at high risk of adverse outcomes • Singleton babies born at term (37 to 42 weeks of pregnancy) with no previously identified problems (for example congenital malformations, genetic anomalies, intrauterine growth restriction, placental problems)
Intervention	Face-to-face clinical review advised as soon as possible (< 3 hours) after a mother telephoning to report PRoM
Comparator	<p>Face-to-face clinical review delayed between the timeframes stated below after a mother telephoning to report PRoM</p> <ul style="list-style-type: none"> • 3 to < 6 hours • 6 to < 12 hours • 12 < 18 hours • 18 to 24 hours • > 24 hours
Types of study to be included	<p>Include published full-text papers:</p> <ul style="list-style-type: none"> • Systematic reviews of RCTs • Parallel RCTs (individual or cluster) <p>If not enough evidence from RCTs is found:</p> <ul style="list-style-type: none"> • Prospective and retrospective cohort studies <p>Note: prospective and retrospective studies must make adjustment for confounding factors in their analysis</p> <p>Conference abstracts will not be included because these do not typically have sufficient information to allow full critical appraisal.</p>

Field	Content
Other exclusion criteria	<p>Population:</p> <ul style="list-style-type: none"> • Women who are identified before labour to be at high risk, or whose baby is at high risk, of complications or adverse outcomes • Women with non-cephalic presentation • Women with an intrauterine fetal death • Women pregnant with multiple babies <p>Setting:</p> <ul style="list-style-type: none"> • Countries other than high income countries (as defined by the OECD) <p>If any study or systematic review includes <1/3 of women with the above characteristics/ who received care in the above setting, it will be considered for inclusion but, if included, the evidence will be downgraded for indirectness.</p>
Context	The population of this guideline may overlap with the population of women included in other NICE guidelines (such as caesarean birth or preterm labour and birth)
Primary outcomes (critical outcomes)	<ul style="list-style-type: none"> • Maternal admission to intensive therapy unit (ITU) or high-dependency area • Mode of birth (spontaneous vaginal, instrumental vaginal, caesarean birth) • Requirement for antibiotics
Secondary outcomes (important outcomes)	<ul style="list-style-type: none"> • Induction of labour • Evidence of maternal infection including maternal pyrexia, other signs of chorioamnionitis and sepsis • Women's experience of labour and birth • Neonatal admission (includes neonatal intensive care unit [NICU] and special care baby unit [SCBU])
Data extraction (selection and coding)	<p>All references identified by the searches and from other sources will be uploaded into EPPI and de-duplicated. Titles and abstracts of the retrieved citations will be screened to identify studies that potentially meet the inclusion criteria outlined in the review protocol. Duplicate screening will not be undertaken for this question.</p> <p>Full versions of the selected studies will be obtained for assessment. Studies that fail to meet the inclusion criteria once the full version has been checked will be excluded at this stage. Each study excluded after checking the full version will be listed, along with the reason for its exclusion.</p> <p>A standardised form will be used to extract data from studies. The following data will be extracted: study details (reference, country where study was carried out, type and dates), participant characteristics, inclusion and exclusion criteria, details of the interventions if relevant, setting and follow-up, relevant outcome data and source of funding. One reviewer will extract relevant</p>

Field	Content
Risk of bias (quality) assessment	<p>data into a standardised form, and this will be quality assessed by a senior reviewer.</p> <p>Quality assessment of individual studies will be performed using the following checklists:</p> <ul style="list-style-type: none"> • ROBIS tool for systematic reviews • Cochrane RoB tool v.2 for RCTs • Cochrane RoB tool v.2 for cluster randomised controlled trials • ROBINS-I tool for non-randomised (clinical) controlled trials and cohort studies <p>The quality assessment will be performed by one reviewer and this will be quality assessed by a senior reviewer.</p>
Strategy for data synthesis	<p>Quantitative findings will be formally summarised in the review. Where multiple studies report on the same outcome for the same comparison, meta-analyses will be conducted using Cochrane Review Manager software.</p> <p>A fixed effect meta-analysis will be conducted and data will be presented as risk ratios if possible or odds ratios when required (for example, if only available in this form in included studies) for dichotomous outcomes, and mean differences or standardised mean differences for continuous outcomes. Heterogeneity in the effect estimates of the individual studies will be assessed using the I² statistic. Alongside visual inspection of the point estimates and confidence intervals, I² values of greater than 50% and 80% will be considered as significant and very significant heterogeneity, respectively. Heterogeneity will be explored as appropriate using sensitivity analyses and pre-specified subgroup analyses. If heterogeneity cannot be explained through subgroup analysis then a random effects model will be used for meta-analysis, or the data will not be pooled.</p> <p>The confidence in the findings across all available evidence will be evaluated for each outcome using an adaptation of the 'Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox' developed by the international GRADE working group: http://www.gradeworkinggroup.org/</p> <p>Minimally important differences:</p> <ul style="list-style-type: none"> • Validated scales/continuous outcomes: published MIDs where available • All other outcomes & where published MIDs are not available: 0.8 and 1.25 for all relative dichotomous outcomes ; +/- 0.5x control group SD for continuous outcomes
Analysis of subgroups	<p>Evidence will be stratified by:</p> <ul style="list-style-type: none"> • BMI thresholds on booking: <ul style="list-style-type: none"> ○ Underweight range: <18.5 kg/m² ○ Healthy weight range: 18.5 to 24.9 kg/m² ○ Overweight range: 25 to 29.99 kg/m² ○ Obesity range 1: 30 to 34.99 kg/m²

Field	Content
	<ul style="list-style-type: none"> ○ Obesity range 2: 35 to 39.99 kg/m² ● Confirmed vs suspected PRoM <p>Stratifications will be dealt with in a hierarchy (this is, first by BMI thresholds on booking and then by confirmed vs suspected PRoM)</p> <p>Evidence will be subgrouped by the following only in the event that there is significant heterogeneity in outcomes:</p> <ul style="list-style-type: none"> ● Age of woman (<35 vs ≥ 35) ● Ethnicity <ul style="list-style-type: none"> ○ White ○ Asian/Asian British ○ Black/African/Caribbean/Black British ○ Mixed/Multiple ethnic groups ○ Other ethnic group ● Women with disability vs not ● Deprived socioeconomic group vs not <p>Where evidence is stratified or subgrouped the committee will consider on a case by case basis if separate recommendations should be made for distinct groups. Separate recommendations may be made where there is evidence of a differential effect of interventions in distinct groups. If there is a lack of evidence in one group, the committee will consider, based on their experience, whether it is reasonable to extrapolate and assume the interventions will have similar effects in that group compared with others.</p>
Type and method of review	<input checked="" type="checkbox"/> Intervention <input type="checkbox"/> Diagnostic <input type="checkbox"/> Prognostic <input type="checkbox"/> Qualitative <input type="checkbox"/> Epidemiologic <input type="checkbox"/> Service Delivery <input type="checkbox"/> Other (please specify)
Language	English

Field	Content
Country	England
Anticipated or actual start date	14/07/2021
Anticipated completion date	22/03/2023
Named contact	<p>5a. Named contact Guideline Development Team National Guideline Alliance (NGA)</p> <p>5b. Named contact e-mail IPCupdate@nice.org.uk</p> <p>5c. Organisational affiliation of the review Guideline Development Team NGA, Centre for Guidelines, National Institute for Health and Care Excellence (NICE)</p>
Review team members	<p>From the Guideline Development Team NGA:</p> <ul style="list-style-type: none"> • Senior Systematic Reviewer • Systematic Reviewer
Funding sources/sponsor	This systematic review is being completed by the Guideline Development Team NGA, Centre for Guidelines, which is part of the National Institute for Health and Care Excellence (NICE).
Conflicts of interest	All guideline committee members and anyone who has direct input into NICE guidelines (including the evidence review team and expert witnesses) must declare any potential conflicts of interest in line with NICE's code of practice for declaring and dealing with conflicts of interest. Any relevant interests, or changes to interests, will also be declared publicly at the start of each guideline committee meeting. Before each meeting, any potential conflicts of interest will be considered by the guideline committee Chair and a senior member of the development team. Any decisions to exclude a person from all or part of a meeting will be documented. Any changes to a member's declaration of interests will be recorded in the minutes of the meeting. Declarations of interests will be published with the final guideline.
Collaborators	Development of this systematic review will be overseen by an advisory committee who will use the review to inform the development of evidence-based recommendations in line with section 3 of Developing NICE guidelines: the manual . Members of the guideline committee are available on the NICE website: https://www.nice.org.uk/guidance/cg190
Other registration	None

Field	Content
details	
URL for published protocol	https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=266237
Dissemination plans	NICE may use a range of different methods to raise awareness of the guideline. These include standard approaches such as: <ul style="list-style-type: none"> • notifying registered stakeholders of publication • publicising the guideline through NICE's newsletter and alerts • issuing a press release or briefing as appropriate, posting news articles on the NICE website, using social media channels, and publicising the guideline within NICE.
Keywords	Pre-labour rupture of membranes; timeframe; clinical review
Details of existing review of same topic by same authors	Not applicable
Additional information	None
Details of final publication	www.nice.org.uk

1 CDSR: Cochrane Database of Systematic Reviews; CENTRAL: Cochrane Central Register of Controlled Trials; GRADE: Grading of Recommendations Assessment,
2 Development and Evaluation; IHTA: International Health Technology Assessment; MID: minimally important difference; NGA: National Guideline Alliance; NHS: National health
3 service; NICE: National Institute for Health and Care Excellence; OECD: Organisation for Economic Co-operation and Development; PRESS: peer review of electronic search
4 strategies; PRoM: Pre-labour rupture of membranes; RCT: randomised controlled trial; ROBINS-I: Risk of bias in non-randomised studies on interventions; RoB(IS): risk of bias
5 (in systematic reviews); SD: standard deviation
6

Appendix B Literature search strategies

Literature search strategies for review question: What is the optimum timeframe between a mother reporting possible P_{Ro}M and face-to-face clinical review?

Review question search strategies

Database: Medline – OVID interface

Date of last search: 06/12/2022

#	Searches
1	FETAL MEMBRANES, PREMATURE RUPTURE/
2	((prelabo?r or pre-labo?r or preterm or pre-term or premature*) adj3 ruptur* adj3 membrane?).ti,ab.
3	((prelabo?r or pre-labo?r or preterm or pre-term or premature*) adj3 ROM).ti,ab.
4	PPROM.ti,ab.
5	(water* adj10 break* adj10 (prelabo?r or pre-labo?r or preterm or pre-term or premature*)).ti,ab.
6	or/1-5
7	(fluid? adj3 (gush* or trickl* or leak*)).ti,ab.
8	(feel* adj3 (wet* or damp*)).ti,ab.
9	((urinat* or wee*) adj3 (sensation? or feel* or need*)).ti,ab.
10	or/7-9
11	PREGNANCY/
12	pregnan*.ti,ab.
13	or/11-12
14	10 and 13
15	6 or 14
16	"REFERRAL AND CONSULTATION"/
17	clinical\$ review\$.ti,ab.
18	face to face.ti,ab.
19	consultation?.ti,ab.
20	meeting?.ti,ab.
21	clinical\$ examin\$.ti,ab.
22	(examin* adj3 (patient? or wom?n)).ti,ab.
23	(contact* adj5 (healthcare professional? or medic? or doctor? or consultant? or specialist? or obstetrician? or gyn?ecologist? or midwife? or midwive? or GP or GPs or nurse? or hospital? or ward? or department?)).ti,ab.
24	TRIAGE/
25	triag*.ti,ab.
26	HOTLINES/
27	exp TELEPHONE/
28	(hotline? or phone? or telephone? or phoning or phoned).ti,ab.
29	or/16-28
30	15 and 29
31	FETAL MEMBRANES, PREMATURE RUPTURE/di [Diagnosis]
32	TIME FACTORS/
33	31 and 32
34	30 or 33
35	limit 34 to english language
36	LETTER/
37	EDITORIAL/
38	NEWS/
39	exp HISTORICAL ARTICLE/
40	ANECDOTES AS TOPIC/
41	COMMENT/
42	CASE REPORT/
43	(letter or comment*).ti.
44	or/36-43
45	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
46	44 not 45
47	ANIMALS/ not HUMANS/
48	exp ANIMALS, LABORATORY/
49	exp ANIMAL EXPERIMENTATION/
50	exp MODELS, ANIMAL/
51	exp RODENTIA/
52	(rat or rats or mouse or mice).ti.

#	Searches
53	or/46-52
54	35 not 53
55	META-ANALYSIS/
56	META-ANALYSIS AS TOPIC/
57	(meta analy* or metanaly* or metaanaly*).ti,ab.
58	((systematic* or evidence*) adj2 (review* or overview*)),ti,ab.
59	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
60	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
61	(search* adj4 literature).ab.
62	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
63	cochrane.jw.
64	or/55-63
65	randomized controlled trial.pt.
66	controlled clinical trial.pt.
67	pragmatic clinical trial.pt.
68	randomi#ed.ab.
69	placebo.ab.
70	randomly.ab.
71	CLINICAL TRIALS AS TOPIC/
72	trial.ti.
73	or/65-72
74	COHORT STUDIES/
75	FOLLOW-UP STUDIES/
76	LONGITUDINAL STUDIES/
77	PROSPECTIVE STUDIES/
78	RETROSPECTIVE STUDIES/
79	((cohort* or follow-up or follow?up or longitudinal* or prospective* or retrospective*) adj1 (stud* or research or analys*)),tw.
80	(incidence? adj (stud* or research or analys*)),tw.
81	(longitudinal* adj1 (survey* or evaluat*)),tw.
82	(prospective* adj method*)),tw.
83	(retrospective* adj design*)),tw.
84	or/74-83
85	54 and 64
86	54 and 73
87	54 and 84
88	or/85-87

Database: Embase – OVID interface

Date of last search: 06/12/2022

#	Searches
1	PREMATURE FETUS MEMBRANE RUPTURE/
2	((prelabo?r or pre-labo?r or preterm or pre-term or premature*) adj3 ruptur* adj3 membrane?).ti,ab.
3	((prelabo?r or pre-labo?r or preterm or pre-term or premature*) adj3 ROM).ti,ab.
4	PPROM.ti,ab.
5	(water* adj10 break* adj10 (prelabo?r or pre-labo?r or preterm or pre-term or premature*)),ti,ab.
6	or/1-5
7	(fluid? adj3 (gush* or trickl* or leak*)),ti,ab.
8	(feel* adj3 (wet* or damp*)),ti,ab.
9	((urinat* or wee*) adj3 (sensation? or feel* or need*)),ti,ab.
10	or/7-9
11	PREGNANCY/
12	pregnan*.ti,ab.
13	or/11-12
14	10 and 13
15	6 or 14
16	CONSULTATION/
17	PATIENT REFERRAL/
18	clinical\$ review\$.ti,ab.
19	face to face.ti,ab.
20	consultation?.ti,ab.
21	meeting?.ti,ab.
22	clinical\$ examin\$.ti,ab.
23	(examin* adj3 (patient? or wom?n)).ti,ab.
24	(contact* adj5 (healthcare professional? or medic? or doctor? or consultant? or specialist? or obstetrician? or gyn?ecologist? or midwife? or midwive? or GP or GPs or nurse? or hospital? or ward? or department?)),ti,ab.

#	Searches
25	triag*.ti,ab.
26	HOTLINE/
27	TELEPHONE/
28	exp MOBILE PHONE/
29	(hotline? or phone? or telephone? or phoning or phoned).ti,ab.
30	or/16-29
31	15 and 30
32	PREMATURE FETUS MEMBRANE RUPTURE/di [Diagnosis]
33	TIME FACTOR/
34	32 and 33
35	31 or 34
36	limit 35 to english language
37	LETTER/
38	EDITORIAL/
39	NEWS/
40	exp HISTORICAL ARTICLE/
41	ANECDOTES AS TOPIC/
42	COMMENT/
43	CASE REPORT/
44	(letter or comment*).ti.
45	or/37-44
46	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
47	45 not 46
48	ANIMALS/ not HUMANS/
49	exp ANIMALS, LABORATORY/
50	exp ANIMAL EXPERIMENTATION/
51	exp MODELS, ANIMAL/
52	exp RODENTIA/
53	(rat or rats or mouse or mice).ti.
54	or/47-53
55	36 not 54
56	SYSTEMATIC REVIEW/
57	META-ANALYSIS/
58	(meta analy* or metanaly* or metaanaly*).ti,ab.
59	((systematic or evidence) adj2 (review* or overview*)).ti,ab.
60	(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
61	(search strategy or search criteria or systematic search or study selection or data extraction).ab.
62	(search* adj4 literature).ab.
63	(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.
64	((pool* or combined) adj2 (data or trials or studies or results)).ab.
65	cochrane.jw.
66	or/56-65
67	random*.ti,ab.
68	factorial*.ti,ab.
69	(crossover* or cross over*).ti,ab.
70	((doubl* or singl*) adj blind*).ti,ab.
71	(assign* or allocat* or volunteer* or placebo*).ti,ab.
72	CROSSOVER PROCEDURE/
73	SINGLE BLIND PROCEDURE/
74	RANDOMIZED CONTROLLED TRIAL/
75	DOUBLE BLIND PROCEDURE/
76	or/67-75
77	COHORT ANALYSIS/
78	FOLLOW UP/
79	LONGITUDINAL STUDY/
80	PROSPECTIVE STUDY/
81	RETROSPECTIVE STUDIES/
82	((cohort* or follow-up or follow?up or longitudinal* or prospective* or retrospective*) adj1 (stud* or research or analys*)).tw.
83	(incidence? adj (stud* or research or analys*)).tw.
84	(longitudinal* adj1 (survey* or evaluat*)).tw.
85	(prospective* adj method*).tw.
86	(retrospective* adj design*).tw.
87	or/77-86
88	55 and 66
89	55 and 76
90	55 and 87
91	or/88-90

Databases: Cochrane Central Register of Controlled Trials; and Cochrane Database of Systematic Reviews – Wiley interface

Date of last search: 06/12/2022

#	Searches
#1	MeSH descriptor: [Fetal Membranes, Premature Rupture] this term only
#2	((prelabor or prelabour or pre-labor or pre-labour or preterm or pre-term or premature*) near/3 ruptur* near/3 membrane*):ti,ab
#3	((prelabor or prelabour or pre-labor or pre-labour or preterm or pre-term or premature*) near/3 ROM):ti,ab
#4	PPROM:ti,ab
#5	(water* near/10 break* near/10 (prelabor or prelabour or pre-labor or pre-labour or preterm or pre-term or premature*)):ti,ab
#6	#1 or #2 or #3 or #4 or #5
#7	(fluid* near/3 (gush* or trickl* or leak*)):ti,ab
#8	(feel* near/3 (wet* or damp*)):ti,ab
#9	((urinat* or wee*) near/3 (sensation* or feel* or need*)):ti,ab
#10	#7 or #8 or #9
#11	MeSH descriptor: [Pregnancy] this term only
#12	pregnan*:ti,ab
#13	#11 or #12
#14	#10 and #13
#15	#6 or #14
#16	MeSH descriptor: [Referral and Consultation] this term only
#17	"Clinical* review*":ti,ab
#18	"face to face":ti,ab
#19	consultation*:ti,ab
#20	meeting*:ti,ab
#21	"clinical* examin*":ti,ab
#22	(examin* near/3 (patient or patients or woman or women)):ti,ab
#23	(contact* near/5 ("healthcare professional*" or medic or medics or doctor or doctors or consultant* or specialist* or obstetrician* or gynecologist* or gynaecologist* or midwife* or midwife* or GP or GPs or nurse* or hospital or hospitals or ward or wards or department or departments)):ti,ab
#24	MeSH descriptor: [Triage] this term only
#25	triag*:ti,ab
#26	MeSH descriptor: [Hotlines] this term only
#27	MeSH descriptor: [Telephone] explode all trees
#28	(hotline* or phone* or telephone* or phoning or phoned):ti,ab
#29	#16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
#30	#15 and #29
#31	MeSH descriptor: [Fetal Membranes, Premature Rupture] this term only and with qualifier(s): [diagnosis - DI]
#32	MeSH descriptor: [Time Factors] this term only
#33	#31 and #32
#34	#30 or #33

Database: International Health Technology Assessment

Date of last search: 06/12/2022

#	Searches
	All: "Fetal Membranes, Premature Rupture"[mh]
	OR All: (rupture) AND (membranes)
	OR All: (PPROM)
	OR All: (waters) AND (breaking)

Health economics search strategies

Database: Medline – OVID interface

Date of last search: 06/12/2022

#	Searches
1	FETAL MEMBRANES, PREMATURE RUPTURE/
2	((prelabo?r or pre-labo?r or preterm or pre-term or premature*) adj3 ruptur* adj3 membrane?).ti,ab.
3	((prelabo?r or pre-labo?r or preterm or pre-term or premature*) adj3 ROM).ti,ab.
4	PPROM.ti,ab.
5	(water* adj10 break* adj10 (prelabo?r or pre-labo?r or preterm or pre-term or premature*)).ti,ab.
6	or/1-5
7	(fluid? adj3 (gush* or trickl* or leak*)).ti,ab.
8	(feel* adj3 (wet* or damp*)).ti,ab.
9	((urinat* or wee*) adj3 (sensation? or feel* or need*)).ti,ab.
10	or/7-9
11	PREGNANCY/
12	pregnan*.ti,ab.
13	or/11-12
14	10 and 13
15	6 or 14
16	"REFERRAL AND CONSULTATION"/
17	clinical\$ review\$.ti,ab.
18	face to face.ti,ab.
19	consultation?.ti,ab.
20	meeting?.ti,ab.
21	clinical\$ examin\$.ti,ab.
22	(examin* adj3 (patient? or wom?n)).ti,ab.
23	(contact* adj5 (healthcare professional? or medic? or doctor? or consultant? or specialist? or obstetrician? or gyn?ecologist? or midwife? or midwive? or GP or GPs or nurse? or hospital? or ward? or department?)).ti,ab.
24	TRIAGE/
25	triag*.ti,ab.
26	HOTLINES/
27	exp TELEPHONE/
28	(hotline? or phone? or telephone? or phoning or phoned).ti,ab.
29	or/16-28
30	15 and 29
31	FETAL MEMBRANES, PREMATURE RUPTURE/di [Diagnosis]
32	TIME FACTORS/
33	31 and 32
34	30 or 33
35	limit 34 to english language
36	LETTER/
37	EDITORIAL/
38	NEWS/
39	exp HISTORICAL ARTICLE/
40	ANECDOTES AS TOPIC/
41	COMMENT/
42	CASE REPORT/
43	(letter or comment*).ti.
44	or/36-43
45	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
46	44 not 45
47	ANIMALS/ not HUMANS/
48	exp ANIMALS, LABORATORY/
49	exp ANIMAL EXPERIMENTATION/
50	exp MODELS, ANIMAL/
51	exp RODENTIA/
52	(rat or rats or mouse or mice).ti.
53	or/46-52
54	35 not 53
55	ECONOMICS/
56	VALUE OF LIFE/
57	exp "COSTS AND COST ANALYSIS"/
58	exp ECONOMICS, HOSPITAL/
59	exp ECONOMICS, MEDICAL/
60	exp RESOURCE ALLOCATION/
61	ECONOMICS, NURSING/
62	ECONOMICS, PHARMACEUTICAL/
63	exp "FEES AND CHARGES"/
64	exp BUDGETS/
65	budget*.ti,ab.
66	cost*.ti,ab.
67	(economic* or pharmaco?economic*).ti,ab.
68	(price* or pricing*).ti,ab.
69	(financ* or fee or fees or expenditure* or saving*).ti,ab.

#	Searches
70	(value adj2 (money or monetary)).ti,ab.
71	resourc* allocat*.ti,ab.
72	(fund or funds or funding* or funded).ti,ab.
73	(ration or rations or rationing* or rationed).ti,ab.
74	ec.fs.
75	or/55-74
76	54 and 75

Database: Embase – OVID interface

Date of last search: 06/12/2022

#	Searches
1	PREMATURE FETUS MEMBRANE RUPTURE/
2	((prelabo?r or pre-labo?r or preterm or pre-term or premature*) adj3 ruptur* adj3 membrane?).ti,ab.
3	((prelabo?r or pre-labo?r or preterm or pre-term or premature*) adj3 ROM).ti,ab.
4	PPROM.ti,ab.
5	(water* adj10 break* adj10 (prelabo?r or pre-labo?r or preterm or pre-term or premature*)).ti,ab.
6	or/1-5
7	(fluid? adj3 (gush* or trickl* or leak*)).ti,ab.
8	(feel* adj3 (wet* or damp*)).ti,ab.
9	((urinatt* or wee*) adj3 (sensation? or feel* or need*)).ti,ab.
10	or/7-9
11	PREGNANCY/
12	pregnan*.ti,ab.
13	or/11-12
14	10 and 13
15	6 or 14
16	CONSULTATION/
17	PATIENT REFERRAL/
18	clinical\$ review\$.ti,ab.
19	face to face.ti,ab.
20	consultation?.ti,ab.
21	meeting?.ti,ab.
22	clinical\$ examin\$.ti,ab.
23	(examin* adj3 (patient? or wom?n)).ti,ab.
24	(contact* adj5 (healthcare professional? or medic? or doctor? or consultant? or specialist? or obstetrician? or gyn?ecologist? or midwife? or midwife? or GP or GPs or nurse? or hospital? or ward? or department?)).ti,ab.
25	triag*.ti,ab.
26	HOTLINE/
27	TELEPHONE/
28	exp MOBILE PHONE/
29	(hotline? or phone? or telephone? or phoning or phoned).ti,ab.
30	or/16-29
31	15 and 30
32	PREMATURE FETUS MEMBRANE RUPTURE/di [Diagnosis]
33	TIME FACTOR/
34	32 and 33
35	31 or 34
36	limit 35 to english language
37	LETTER/
38	EDITORIAL/
39	NEWS/
40	exp HISTORICAL ARTICLE/
41	ANECDOTES AS TOPIC/
42	COMMENT/
43	CASE REPORT/
44	(letter or comment*).ti.
45	or/37-44
46	RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab.
47	45 not 46
48	ANIMALS/ not HUMANS/
49	exp ANIMALS, LABORATORY/
50	exp ANIMAL EXPERIMENTATION/
51	exp MODELS, ANIMAL/
52	exp RODENTIA/
53	(rat or rats or mouse or mice).ti.
54	or/47-53
55	36 not 54

#	Searches
56	HEALTH ECONOMICS/
57	exp ECONOMIC EVALUATION/
58	exp HEALTH CARE COST/
59	exp FEE/
60	BUDGET/
61	FUNDING/
62	RESOURCE ALLOCATION/
63	budget*.ti,ab.
64	cost*.ti,ab.
65	(economic* or pharmaco?economic*).ti,ab.
66	(price* or pricing*).ti,ab.
67	(financ* or fee or fees or expenditure* or saving*).ti,ab.
68	(value adj2 (money or monetary)).ti,ab.
69	resourc* allocat*.ti,ab.
70	(fund or funds or funding* or funded).ti,ab.
71	(ration or rations or rationing* or rationed).ti,ab.
72	or/56-71
73	55 and 72

Database: Cochrane Central Register of Controlled Trials – Wiley interface

Date of last search: 06/12/2022

#	Searches
#1	MeSH descriptor: [Fetal Membranes, Premature Rupture] this term only
#2	((prelabor or prelabour or pre-labor or pre-labour or preterm or pre-term or premature*) near/3 ruptur* near/3 membrane*):ti,ab
#3	((prelabor or prelabour or pre-labor or pre-labour or preterm or pre-term or premature*) near/3 ROM):ti,ab
#4	PPROM:ti,ab
#5	(water* near/10 break* near/10 (prelabor or prelabour or pre-labor or pre-labour or preterm or pre-term or premature*)):ti,ab
#6	#1 or #2 or #3 or #4 or #5
#7	(fluid* near/3 (gush* or trickl* or leak*)):ti,ab
#8	(feel* near/3 (wet* or damp*)):ti,ab
#9	((urin* or wee*) near/3 (sensation* or feel* or need*)):ti,ab
#10	#7 or #8 or #9
#11	MeSH descriptor: [Pregnancy] this term only
#12	pregnan*:ti,ab
#13	#11 or #12
#14	#10 and #13
#15	#6 or #14
#16	MeSH descriptor: [Referral and Consultation] this term only
#17	"Clinical* review*":ti,ab
#18	"face to face":ti,ab
#19	consultation*:ti,ab
#20	meeting*:ti,ab
#21	"clinical* examin*":ti,ab
#22	(examin* near/3 (patient or patients or woman or women)):ti,ab
#23	(contact* near/5 ("healthcare professional*" or medic or medics or doctor or doctors or consultant* or specialist* or obstetrician* or gynecologist* or gynaecologist* or midwife* or midwives* or GP or GPs or nurse* or hospital or hospitals or ward or wards or department or departments)):ti,ab
#24	MeSH descriptor: [Triage] this term only
#25	triag*:ti,ab
#26	MeSH descriptor: [Hotlines] this term only
#27	MeSH descriptor: [Telephone] explode all trees
#28	(hotline* or phone* or telephone* or phoning or phoned):ti,ab
#29	#16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
#30	#15 and #29
#31	MeSH descriptor: [Fetal Membranes, Premature Rupture] this term only and with qualifier(s): [diagnosis - DI]
#32	MeSH descriptor: [Time Factors] this term only
#33	#31 and #32
#34	#30 or #33
#35	MeSH descriptor: [Economics] this term only
#36	MeSH descriptor: [Value of Life] this term only
#37	MeSH descriptor: [Costs and Cost Analysis] explode all trees
#38	MeSH descriptor: [Economics, Hospital] explode all trees
#39	MeSH descriptor: [Economics, Medical] explode all trees
#40	MeSH descriptor: [Resource Allocation] explode all trees
#41	MeSH descriptor: [Economics, Nursing] this term only

#	Searches
#42	MeSH descriptor: [Economics, Pharmaceutical] this term only
#43	MeSH descriptor: [Fees and Charges] explode all trees
#44	MeSH descriptor: [Budgets] explode all trees
#45	budget*:ti,ab
#46	cost*:ti,ab
#47	(economic* or pharmaco?economic*):ti,ab
#48	(price* or pricing*):ti,ab
#49	(financ* or fee or fees or expenditure* or saving*):ti,ab
#50	(value near/2 (money or monetary)):ti,ab
#51	resourc* allocat*:ti,ab
#52	(fund or funds or funding* or funded):ti,ab
#53	(ration or rations or rationing* or rationed):ti,ab
#54	#35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53
#55	#34 and #54

Database: International Health Technology Assessment


Date of last search: 06/12/2022

#	Searches
	All: "Fetal Membranes, Premature Rupture"[mh]
	OR All: (rupture) AND (membranes)
	OR All: (PPROM)
	OR All: (waters) AND (breaking)

Appendix C Effectiveness evidence study selection

Study selection for: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?

Figure 1: Study selection flow chart



Appendix D Evidence tables

Evidence tables for review question: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?

No evidence was identified which was applicable to this review question.

Appendix E Forest plots

Forest plots for review question: What is the optimum timeframe between a mother reporting possible P_{RoM} and face-to-face clinical review?

No meta-analysis was conducted for this review question and so there are no forest plots.

Appendix F GRADE tables

GRADE tables for review question: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?


No evidence was identified which was applicable to this review question.

Appendix G Economic evidence study selection

Study selection for: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?

No economic evidence was identified which was applicable to this review question.

Figure 2: Study selection flow chart



Appendix H Economic evidence tables

Economic evidence tables for review question: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?

No evidence was identified which was applicable to this review question.

Appendix I Economic model

Economic model for review question: What is the optimum timeframe between a mother reporting possible PROM and face-to-face clinical review?

No economic analysis was conducted for this review question.

Appendix J Excluded studies

Excluded studies for review question: What is the optimum timeframe between a mother reporting possible P_{RoM} and face-to-face clinical review?

Excluded effectiveness

Table 3: Excluded studies and reasons for their exclusion

Study	Reason for exclusion
Carlan, S. J., O'Brien, W. F., Parsons, M. T. et al. (1993) Preterm premature rupture of membranes: a randomized study of home versus hospital management. <i>Obstetrics and gynecology</i> 81(1): 61-4	- Intervention not in PICO Study compares latency periods of women diagnosed with P _{RoM} randomised to home or hospital management. Study does not report timeframe from presentation/ reporting of possible P _{RoM} to clinical assessment/ review
Chacon, Kelly M.; Bryant Mantha, Allison S.; Clapp, Mark A. (2021) Outpatient Expectant Management of Term Prelabor Rupture of Membranes: A Retrospective Cohort Study. <i>American journal of perinatology</i> 38(7): 714-720	- Intervention not in PICO Study compares latency periods of women diagnosed with P _{RoM} randomised to home or hospital management. Study does not report timeframe from presentation/ reporting of possible P _{RoM} to clinical assessment/ review
Munson, L. A., Graham, A., Koos, B. J. et al. (1985) Is there a need for digital examination in patients with spontaneous rupture of the membranes?. <i>American journal of obstetrics and gynecology</i> 153(5): 562-3	- Intervention not in PICO Study compares two methods of membrane examination. Study does not report timeframe from presentation/ reporting of possible P _{RoM} to clinical assessment/ review
Papadakis, K. and Pande, B. (2017) The role of Actim PROM in the clinical diagnosis of P _{PRoM} . <i>BJOG: An International Journal of Obstetrics and Gynaecology</i> 124(supplement1): 138-139	- Conference abstract
Singhal, Seema; Puri, Manju; Gami, Neha (2012) An analysis of factors affecting the duration of latency period and its impact on neonatal outcome in patients with p _{prom} . <i>International Journal of Infertility and Fetal Medicine</i> 3(3): 87-91	- Intervention not in PICO Prospective cohort study reporting factors associated with length of latency period in women with P _{PRoM} . Study does not report timeframe from presentation/ reporting of possible P _{RoM} to clinical assessment/ review
Warwar, Rachel E., Kuss, Brittany N., Elliott, John O. et al. (2019) Financial Analysis of Expectant Management of Preterm Premature Rupture of Membranes to Term in a Community Hospital. <i>Obstetrics and Gynecology</i> 133(suppl1)	- Conference abstract

Excluded economic studies

No economic evidence was identified for this review.

Appendix K Research recommendations – full details

Research recommendations for review question: What is the optimum timeframe between a mother reporting possible PRoM and face-to-face clinical review?

No research recommendations were made for this review question.